Company profile
S-Evans Biosciences
Cell therapy
Privately held: no public share price · China
Assets
(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
0Diseases
| Target & Modality | |||
|---|---|---|---|
Menstrual blood-derived mesenchymal stem cells (MenSCs)No recent activity | Phase 2 | Pancreatic islet cell replacementCell therapy | Indication not yet linked |
Upcoming events
Research
Sign in to access ResearchUnlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Research
Sign in to access ResearchUnlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.